Mainz Biomed N.V. (MYNZ) Institutional Ownership

Ownership Summary

The institutional landscape for Mainz Biomed N.V. (NASDAQ:MYNZ) includes 15 filers as of the latest reporting cycle ending December 2025.

• Institutional ownership in Mainz Biomed edged up to 31.3% in December 2025, compared to 13.7% in September 2025.
• Quarterly data indicates a 155.54% shift in institutional share volume, and the annual owner count reflects an increase of 87.50%.
• The latest 13F cycle for Mainz Biomed reveals that of 15 total investors, 10 funds grew their exposure, whereas 0 reduced theirs and 5 made no changes.
• Collectively, institutional investors increased their stake in Mainz Biomed to 1.10Mn shares as of December 2025, a change that is up by 668.14K shares quarter on quarter and up 852.39K shares year over year.
• ARMISTICE CAPITAL, LLC continues to be the largest institutional holder of Mainz Biomed as of December 31, 2025, with a position of 775.26K shares, representing 22.11% of the company's outstanding stock.
• Among the most significant buyers of Mainz Biomed during December 2025 were ARMISTICE CAPITAL, LLC (380.74K), Cerity Partners LLC (163.25K), UBS Group AG (47.18K), Steward Partners Investment Advisory, LLC (20.00K), JANE STREET GROUP, LLC (18.44K).
• The top 10 institutional holders of Mainz Biomed for the quarter ending December 2025 included ARMISTICE CAPITAL, LLC (775.26K), Cerity Partners LLC (163.25K), UBS Group AG (54.18K), Steward Partners Investment Advisory, LLC (30.00K), JANE STREET GROUP, LLC (18.44K), Journey Advisory Group, LLC (15.00K), TWO SIGMA SECURITIES, LLC (13.21K), CITADEL ADVISORS LLC (12.64K), CITIGROUP INC (12.30K), OSAIC HOLDINGS, INC. (2.11K).